Trump Administration Opens FDA Docket for First Federally Funded Ibogaine Trials in Opioid Addiction and PTSD

The initiative marks the first direct federal investment in ibogaine clinical research, distinct from prior private or state efforts. The docket requests feedback on dosing, eligibility criteria focused on veterans, cardiac safety monitoring given ibogaine's QT-prolongation risk, and stopping rules. This follows expert calls for rigorous standards after mixed results in smaller observational studies of ibogaine for addiction. Unlike MDMA or psilocybin programs at MAPS and Johns Hopkins, these trials will test a Schedule I compound with limited prior RCT data in U.S. populations.

Broader context reveals tensions in federal psychedelic policy. While the administration funds ibogaine, regulatory pathways for other psychedelics remain stalled at the DEA and FDA. AstraZeneca's parallel $1 billion Cambridge expansion underscores industry focus on established CNS markets rather than novel hallucinogens. Observational data from Mexico and Brazil show short-term reductions in opioid craving, yet lack active controls or long-term abstinence endpoints. Veteran advocacy groups have pushed for inclusion but warn against underpowered safety assessments.

Next steps hinge on docket responses shaping Phase 1/2 protocols. FDA guidance could require ECG telemetry and exclude patients with cardiac history, narrowing enrollment. A successful trial would need to demonstrate superiority over standard methadone or buprenorphine on retention and craving scales, not just surrogate biomarkers. Without such data, ibogaine risks repeating the approval setbacks seen with other Schedule I candidates.